View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
September 6, 2018

Novartis to divest select Sandoz US portfolio to Aurobindo for $900m

Novartis has signed an agreement to sell parts of its Sandoz US business to Aurobindo Pharma USA for a cash consideration of $900m, along with potential earn-outs worth $100m.

Novartis has signed an agreement to sell parts of its Sandoz US business to Aurobindo Pharma USA for a cash consideration of $900m, along with potential earn-outs worth $100m.

Free Report
img

What is the Global Healthcare and Pharma Market Q2 Outlook?

Given the background of high inflation, re-emerging supply chain issues, and the widespread macro-economic implications of the Ukraine conflict, the global pharmaceutical industry is facing an entirely new set of challenges following the turbulence of the COVID-19 pandemic. GlobalData’s World Markets Healthcare (WMH) service has released its latest Q2 forecast. This report incorporates the latest thinking on the opportunities and risks this new environment presents for pharma companies. However, the pharma sector is proving resilient, and we are projecting 4.4% global growth for the year ahead. Yet it remains that the current economic picture is inverting some baseline assumptions from previous quarterly forecasts and altering which markets we expect the key growth levers to derive from. Download our latest executive summary for a snapshot view of what our clients use to formulate winning strategies.
by GlobalData
Enter your details here to receive your free Report.

The deal covers Sandoz generic and branded dermatology businesses, and generic oral solids portfolio in the US.

Sandoz US comprises a total of about 300 products as well as other projects in development phase.

In addition, Aurobindo will gain a dermatology development centre and three manufacturing facilities.

Sandoz expects the divestiture to enable its focus on complex generics, value-added medicines and biosimilars. This is intended to help attain profitable growth over the long-term in the country.

Sandoz CEO Richard Francis said: “Sharpening our portfolio focus in the US allows us to devote more time and resources toward our strategy of bringing complex generics, value-added medicines and biosimilars to patients in the US, creating higher value and opening up access to important medicines where alternatives are truly needed.”

“Sharpening our portfolio focus in the US allows us to devote more time and resources toward our strategy of bringing complex generics, value-added medicines and biosimilars to patients in the US.”

Following closing of the deal, nearly 750 employees from the manufacturing facilities and field representatives for the PharmaDerm branded business may be transferred to Aurobindo.

Sandoz president Carol Lynch said: “We recognise that the transfer of ownership for a business of this size is a complex process, and we are aware that it may create some uncertainties for our associates in the US. It is thus a priority for us to make the transition as clear and quick as possible.”

Subject to customary closing conditions, the transaction is expected to be completed next year.

Sandoz will primarily carry out clinical and business development, and investment operations related to its areas-of-focus, after closing.

In July this year, Aurobindo Pharma’s Indian subsidiary signed an agreement to acquire commercial operations of Apotex International in five European countries.

Related Companies

Free Report
img

What is the Global Healthcare and Pharma Market Q2 Outlook?

Given the background of high inflation, re-emerging supply chain issues, and the widespread macro-economic implications of the Ukraine conflict, the global pharmaceutical industry is facing an entirely new set of challenges following the turbulence of the COVID-19 pandemic. GlobalData’s World Markets Healthcare (WMH) service has released its latest Q2 forecast. This report incorporates the latest thinking on the opportunities and risks this new environment presents for pharma companies. However, the pharma sector is proving resilient, and we are projecting 4.4% global growth for the year ahead. Yet it remains that the current economic picture is inverting some baseline assumptions from previous quarterly forecasts and altering which markets we expect the key growth levers to derive from. Download our latest executive summary for a snapshot view of what our clients use to formulate winning strategies.
by GlobalData
Enter your details here to receive your free Report.

Topics in this article: , ,
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology